NMPA accepted Everest's BLA for LEROCHOL (lerodalcibep) in adult hypercholesterolemia / HeFH.
NMPA · Jul 26🌏 Asia-Pacific Region
Asia-Pacific Pharma Intelligence Center
0 nmpa approvals · 0 trial updates · 0 m&a / licensing · 17 regulatory actions
4.2K drugs · 800 companies · 335 pipeline programs · 1.6K patents Latest signals Global markets overview Data sources Editorial policy Authors
YMYL editorial standards Written and reviewed by the NovaPharmaNews editorial team Editorial policy Methodology Full team
Featured Intelligence
LEQEMBI LEADER Study: Real-World Data at AAIC 2026
Why it matters Nearly 83% of early Alzheimer's patients stayed stable (75.9%) or improved (6.6%) on LEQEMBI.
Watch next Follow source filings, related entities, and follow-on disclosures.
AI Snapshot
What happened today in Asia-Pacific pharma?
LEQEMBI LEADER Study: Real-World Data at AAIC 2026 is the lead NMPA market signal. Nearly 83% of early Alzheimer's patients stayed stable (75.9%) or improved (6.6%) on LEQEMBI.
- Nearly 83% of early Alzheimer's patients stayed stable (75.9%) or improved (6.6%) on LEQEMBI.
NMPA Market Pulse
Data snapshot · 2026-06-17 3 NMPA catalysts (7d) Regulatory & clinical
3 Stories this week Published intelligence
31 Breaking alerts Active now
13 Upcoming events In this market
High-Authority Trackers
Daily-use intelligence tools
0 NMPA Tracker Drug approvals and label decisions 0 Clinical Trial Tracker Phase I-IV updates and safety signals 0 M&A Tracker Deals, licensing, and partnerships IP Patent Expiry Tracker Loss-of-exclusivity opportunities 3 Upcoming Catalysts PDUFA dates, readouts, conferences PDF Research Library Whitepapers and market reports
Market Signals
What is moving in Asia-Pacific pharma
Regulatory
View allNMPA approved an IND for SKB575/HBM7575 in asthma.
NMPA · Jul 26ARTEMIS-008 met OS versus topotecan at a pre-specified interim analysis in relapsed/advanced SCLC after platinum therapy.
NMPA · Jul 26Clinical & Trials
View allNo active signals in this lane yet. Explore the full archive.
Corporate & Deals
View allNo active signals in this lane yet. Explore the full archive.
Trending Entity Network
Companies, drugs, and diseases to follow
Trending Companies
Profile links Pfizer news, pipeline programs, patents, approvals, and NMPA market signals.
Profile links Janssen Research & news, pipeline programs, patents, approvals, and NMPA market signals.
Profile links HOFFMANN-LA ROCHE news, pipeline programs, patents, approvals, and NMPA market signals.
Profile links Novartis news, pipeline programs, patents, approvals, and NMPA market signals.
Profile links MSD Merck Sharp news, pipeline programs, patents, approvals, and NMPA market signals.
Trending Drugs
pembrolizumab connects approvals, trials, patents, competitors, and company exposure.
semaglutide connects approvals, trials, patents, competitors, and company exposure.
tirzepatide connects approvals, trials, patents, competitors, and company exposure.
nivolumab connects approvals, trials, patents, competitors, and company exposure.
dupilumab connects approvals, trials, patents, competitors, and company exposure.
Trending Diseases & Hubs
Oncology HubNMPA oncology news, drugs, trials, events, and companies.
Obesity HubGLP-1, GIP/GLP-1, metabolic approvals, trials, and market access.
Rare Disease HubOrphan drugs, genetic medicines, designations, and sponsor activity.
Neurology HubAlzheimer’s, CNS, neuromuscular, and neurodegeneration intelligence.
Cell & Gene TherapyAdvanced therapies, manufacturing, approval pathways, and readouts.
Pharma Knowledge Graph
Disease to drug to trial to company to approval
Every signal routes into structured entity pages so readers can move from a regional market event to related drugs, sponsors, patents, trials, regulators, events, and market impact.
DiseaseDrugTrialCompanyRegulatorApprovalMarket Impact
Event Ecosystem
This week, must-attend events, and coverage paths
The Health Industry Series – ASEAN (tHIS ASEAN)
Major congress with 0 indexed presentations and 0 companies tracked. · Kuala Lumpur, Malaysia
Asia Bio Partnering Forum 2026
Major congress with 0 indexed presentations and 0 companies tracked. · Singapore
BioJapan 2026
Major congress with 0 indexed presentations and 0 companies tracked. · Yokohama, Japan
Research Library
Whitepapers, reports, and guides
Regional Intelligence FAQ
About the Asia-Pacific Pharma Intelligence Center
What is the Asia-Pacific Pharma Intelligence Center?
It is NovaPharmaNews' regional hub for NMPA approvals, clinical trial updates, company news, events, patents, and market-moving pharmaceutical intelligence.
Which regulator does this regional page track?
The primary regulator tracked on this page is National Medical Products Administration, with related drug, company, clinical trial, patent, and event intelligence.
Who reviews NMPA coverage?
NMPA coverage is written and reviewed by the NovaPharmaNews editorial team. See our editorial policy and author directory.
Partner directory
Browse all suppliers → Pharma Suppliers & Vendors
Independent supplier listings for manufacturing, CRO, and regulatory services.
Partner listings are separate from our editorial newsroom. Supplier profiles do not influence news coverage, rankings, or editorial decisions.
